Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. IONS Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Ionis Pharmaceuticals (IONS)

Market Price (9/18/2025): $61.17 | Market Cap: $9.7 Bil
Sector: Health Care | Industry: Biotechnology

Ionis Pharmaceuticals (IONS)

Market Price (9/18/2025): $61.17
Market Cap: $9.7 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0  Weak multi-year price returns
2Y Excs Rtn is -6.0%, 3Y Excs Rtn is -35%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -472 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -66%
1   Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.6%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.4%
2   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -70%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -79%
3   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.2%
0 Weak multi-year price returns
2Y Excs Rtn is -6.0%, 3Y Excs Rtn is -35%
1 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -472 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -66%
2 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -7.6%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.4%
3 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -70%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -79%
4 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.2%

Market Valuation

 9/18/252024202320222021
Share Price CYE$61.17$34.96$50.59$37.77$30.43
Market Cap CYE ($ Bil)9.75.57.35.44.3
Total Debt ($ Bil)1.41.41.51.41.3
Total Cash ($ Bil)2.12.32.32.02.1
Enterprise Value ($ Bil)9.06.98.86.85.6
Valuation Ratios     
P/S TTM13.57.49.29.15.3
P/EBIT TTM-25.7-13.9-28.0-21.4-173.4
P/E TTM-21.2-11.5-19.8-19.9-150.1
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/18/2520242023
Share Price CYE$61.17$34.96$50.59
Market Cap CYE ($ Bil)9.75.57.3
Total Debt ($ Bil)1.41.41.5
Total Cash ($ Bil)2.12.32.3
Enterprise Value ($ Bil)9.06.98.8
Valuation Ratios   
P/S TTM13.57.49.2
P/EBIT TTM-25.7-13.9-28.0
P/E TTM-21.2-11.5-19.8
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
IONS Return-6%-46%24%34%-31%75%5%
Peers Return114%19%-1%-11%-1%2%124%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ALNY, RARE, SRPT, NTLA, ABBV. See IONS Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Better Bets than Ionis Pharmaceuticals (IONS)

 IONSBetter Performance than IONS
MetricValueIndustry (Biotechnology)
Rev Chg LTM-7.6%ABBV (6.1%), AMGN (12.9%), GILD (3.8%), VRTX (10.5%), REGN (5.4%)
Rev Chg 3Y Avg-1.4%ABBV (0.6%), AMGN (10.0%), GILD (1.6%), VRTX (11.0%), REGN (0.3%)
Op Mgn LTM-65.9%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM-70.0%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM-78.5%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield-4.7%ABBV (3.9%), AMGN (7.8%), GILD (7.3%), VRTX (3.7%), REGN (7.5%)
 IONSBetter Performance than IONS
MetricValueAll Other Sectors
Rev Chg LTM-7.6%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg-1.4%NVDA (92.0%), MSFT (12.5%), AAPL (1.8%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM-65.9%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM-70.0%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM-78.5%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield-4.7%NVDA (2.1%), MSFT (3.3%), AAPL (3.2%), GOOGL (4.1%), AMZN (2.9%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Ionis Pharmaceuticals Earnings Notes  
2IONS Up 40% in One Month: Is It Outperforming Its Rivals?Peer Comparison 
3IONS Dip Buy Analysis  
4Day 8 of Gains Streak for Ionis Pharmaceuticals Stock with 13% Return (vs. 5.1% YTD) [6/9/2025]Notification 
5Ionis Pharmaceuticals Total Shareholder Return (TSR): -30.9% in 2024 and 4.7% 3-yr compounded annual returns (above peer average)  
6Ionis Pharmaceuticals (IONS) Operating Cash Flow ComparisonFinancials 
7Ionis Pharmaceuticals (IONS) Net Income ComparisonFinancials 
8Ionis Pharmaceuticals (IONS) Operating Income ComparisonFinancials 
9Ionis Pharmaceuticals (IONS) Revenue ComparisonFinancials 
10Ionis Pharmaceuticals vs. S&P500 CorrelationCorrelation 
11ARTICLES  
12Buy IONS Stock After Its 35% Pop? September 3rd, 2025
13Market Movers | Winners: CYTK, IONS, UTHR | Losers: UP, SOC, DNA September 2nd, 2025
14What’s Happening With Ionis Pharmaceuticals Stock? December 1st, 2021
15What’s Next For Ionis Pharmaceuticals Stock After A 14% Fall? October 19th, 2021
16Ionis Pharmaceuticals Stock Looks Attractive At $37 June 22nd, 2021
Title
0DASHBOARDS
1Buy IONS Stock After Its 35% Pop?
2Market Movers | Winners: CYTK, IONS, UTHR | Losers: UP, SOC, DNA
3What’s Happening With Ionis Pharmaceuticals Stock?
4What’s Next For Ionis Pharmaceuticals Stock After A 14% Fall?
5Ionis Pharmaceuticals Stock Looks Attractive At $37
6ARTICLES
7Ionis Pharmaceuticals Earnings Notes
8IONS Up 40% in One Month: Is It Outperforming Its Rivals?
9IONS Dip Buy Analysis
10Day 8 of Gains Streak for Ionis Pharmaceuticals Stock with 13% Return (vs. 5.1% YTD) [6/9/2025]
11Ionis Pharmaceuticals Total Shareholder Return (TSR): -30.9% in 2024 and 4.7% 3-yr compounded annual returns (above peer average)
12Ionis Pharmaceuticals (IONS) Operating Cash Flow Comparison
13Ionis Pharmaceuticals (IONS) Net Income Comparison
14Ionis Pharmaceuticals (IONS) Operating Income Comparison
15Ionis Pharmaceuticals (IONS) Revenue Comparison
16Ionis Pharmaceuticals vs. S&P500 Correlation

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11931.7%11931.7%
2GIBOGIBO10714.0% 
3LNZALanzaTech Global8455.2%-86.3%
4GTIGraphjet Technology3998.4%-93.1%
5GWAVGreenwave Technology Solutions3582.8%-91.4%
6QMMMQMMM3409.6%8153.1%
7ECDAECD Automotive Design2715.2%307.9%
8OESXOrion Energy Systems1373.7%14.2%
9OPOceanPal1266.5%-95.6%
10BCTXBriaCell Therapeutics1032.4%-89.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-94.5%-96.0%
2STFSStar Fashion Culture-92.3%-97.9%
3ELPWElong Power-91.1%-76.9%
4NXTTNext Technology-90.1%-95.4%
5EPIXESSA Pharma-89.4%-8.9%
6NAKAKindly MD-88.1% 
7BINIBollinger Innovations-87.6%-100.0%
8JEM707 Cayman-87.4%-98.2%
9YAASYouxin Technology-83.3%-98.4%
10NEONNeonode-82.5%-51.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Ionis Pharmaceuticals

Financials

IONSALNYRARESRPTNTLAABBVMedian
NameIonis Ph.Alnylam .Ultragen.Sarepta .Intellia.AbbVie  
Mkt Price61.17451.7328.7117.0512.41220.8144.94
Mkt Cap9.758.62.81.71.3390.46.3
Rev LTM7172,3486102,4825358,3281,533
Op Inc LTM-472-115-505-1-51213,695-294
FCF LTM-563-75-442-454-42218,239-432
FCF 3Y Avg-438-184-496-505-39620,273-417
CFO LTM-502-45-421-301-41919,283-360
CFO 3Y Avg-401-131-450-395-38721,154-391

Growth & Margins

IONSALNYRARESRPTNTLAABBVMedian
NameIonis Ph.Alnylam .Ultragen.Sarepta .Intellia.AbbVie  
Rev Chg LTM-7.6%17.2%26.8%64.9%15.0%6.1%16.1%
Rev Chg 3Y Avg-1.4%40.8%22.2%45.0%6.2%0.6%14.2%
Rev Chg Q10.1%20.2%13.2%68.4%104.8%6.6%16.7%
QoQ Delta Rev Chg LTM1.7%4.4%3.3%11.1%16.0%1.7%3.9%
Op Mgn LTM-65.9%-4.9%-82.8%-0.0%-968.7%23.5%-35.4%
Op Mgn 3Y Avg-65.7%-27.5%-121.3%-16.1%-991.9%27.2%-46.6%
QoQ Delta Op Mgn LTM1.5%3.0%4.2%5.2%218.7%1.0%3.6%
CFO/Rev LTM-70.0%-1.9%-69.0%-12.1%-791.9%33.1%-40.6%
CFO/Rev 3Y Avg-59.0%-13.1%-93.5%-29.1%-766.0%37.5%-44.0%
FCF/Rev LTM-78.5%-3.2%-72.5%-18.3%-798.0%31.3%-45.4%
FCF/Rev 3Y Avg-64.4%-16.6%-104.0%-35.5%-785.0%36.0%-50.0%

Valuation

IONSALNYRARESRPTNTLAABBVMedian
NameIonis Ph.Alnylam .Ultragen.Sarepta .Intellia.AbbVie  
Mkt Cap9.758.62.81.71.3390.46.3
P/S13.524.94.60.724.46.710.1
P/EBIT-25.7-278.8-6.0-333.7-2.566.3-15.9
P/E-21.2-217.2-5.3-28.8-2.7103.7-13.3
P/CFO-19.4-1,298.5-6.7-5.6-3.120.2-6.1
Total Yield-4.7%-0.5%-18.9%-3.5%-37.3%3.9%-4.1%
Dividend Yield0.0%0.0%0.0%0.0%0.0%2.9%0.0%
FCF Yield 3Y Avg-7.0%-0.8%-14.4%-12.0%-23.9%7.3%-9.5%
D/E0.10.00.00.80.10.20.1
Net D/E-0.1-0.0-0.20.3-0.30.2-0.0

Returns

IONSALNYRARESRPTNTLAABBVMedian
NameIonis Ph.Alnylam .Ultragen.Sarepta .Intellia.AbbVie  
1M Rtn40.8%-1.1%-3.3%-18.8%15.7%6.9%2.9%
3M Rtn65.3%44.6%-23.1%-17.9%29.3%20.1%24.7%
6M Rtn83.5%78.2%-27.6%-78.7%33.4%5.9%19.7%
12M Rtn47.4%64.6%-50.9%-86.4%-45.0%18.2%-13.4%
3Y Rtn32.0%112.1%-37.6%-84.8%-81.1%71.6%-2.8%
1M Excs Rtn38.5%-3.5%-5.7%-21.1%13.3%4.5%0.5%
3M Excs Rtn58.9%36.0%-32.0%-31.2%19.2%9.8%14.5%
6M Excs Rtn68.1%67.4%-43.7%-94.4%17.5%-12.4%2.5%
12M Excs Rtn27.7%53.0%-68.4%-103.6%-61.1%0.4%-30.3%
3Y Excs Rtn-34.9%52.5%-101.7%-145.9%-141.5%13.2%-68.3%

Comparison Analyses

Title
0IONS Up 40% in One Month: Is It Outperforming Its Rivals?
1Ionis Pharmaceuticals vs. Alnylam Pharmaceuticals: With Return Forecast Of 234%, Ionis Pharmaceuticals Is A Better Bet
2Ionis Pharmaceuticals vs. Sarepta Therapeutics: With Return Forecast Of 80%, Ionis Pharmaceuticals Is A Better Bet
3Ionis Pharmaceuticals vs. Crane: With Return Forecast Of 0%, Crane Is A Better Bet
4Ionis Pharmaceuticals vs. Iridium Communications: With Return Forecast Of 48%, Ionis Pharmaceuticals Is A Better Bet
5Ionis Pharmaceuticals vs. MDU Resources Group: With Return Forecast Of 48%, Ionis Pharmaceuticals Is A Better Bet
6Ionis Pharmaceuticals vs. Qualys: With Return Forecast Of 68%, Ionis Pharmaceuticals Is A Better Bet
7Ionis Pharmaceuticals vs. Paylocity Holding: With Return Forecast Of 68%, Ionis Pharmaceuticals Is A Better Bet
8Ionis Pharmaceuticals vs. Enphase Energy: With Return Forecast Of 68%, Ionis Pharmaceuticals Is A Better Bet
9Ionis Pharmaceuticals vs. Penumbra: With Return Forecast Of 85%, Penumbra Is A Better Bet

Financials

$ Mil | FY: 12/312025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q2
Period End3/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/20226/30/2022
Filing Date4/30/20252/19/202511/6/20248/1/20245/7/20242/21/202411/2/20238/9/20235/3/20232/22/202311/9/20228/9/2022
Key Financials Quarterly            
Total Revenue132227134225119325144188131152160134
Ebitda-120-81-117-38-11724-115-52-92-32-41-97
Operating Income-147-111-149-66-150-6-143-90-114-208-59-86
Net Income-147-104-140-66-143-9-147-85-124-52-47-105
EPS-0.93-0.66-0.95-0.45-0.98-0.06-1.03-0.60-0.87-0.37-0.33-0.74
Key Financials TTM            
Total Revenue TTM717705803813777788615631576587875849
Ebitda TTM-356-352-248-245-259-234-290-216-261-22835-3
Operating Income TTM-472-475-370-365-389-354-556-471-467-41017-8
Net Income TTM-458-454-359-366-385-366-409-309-329-2707-28
Growth Rates Quarterly            
Total Revenue Growth10.1%-30.2%-7.2%19.6%-8.4%113.6%-9.7%40.8%-8.0%-65.5%20.0%6.4%
EBITDA Growth-3.0%-439.8%-2.2%27.0%-27.3%175.0%-181.4%46.6%-56.8%-113.7%47.8%-30.1%
Operating Income Growth1.7%-1713.5%-3.7%26.7%-31.0%97.1%-142.3%-5.5%-98.5%-194.7%30.3%-38.8%
Net Income Growth-2.9%-1026.5%4.7%22.3%-14.9%82.3%-213.7%18.9%-90.8%-123.3%43.0%-30.0%
Margins Quarterly            
EBITDA Margin-91.2%-35.5%-87.7%-16.8%-97.5%7.3%-79.6%-27.5%-70.1%-20.8%-25.5%-72.5%
Operating Income Margin-111.7%-48.9%-111.1%-29.3%-125.1%-1.9%-99.4%-47.9%-87.5%-136.9%-37.0%-63.9%
Net Income Margin-111.6%-46.1%-105.0%-29.4%-119.5%-2.9%-102.2%-45.3%-95.2%-34.5%-29.4%-78.6%
Cash & Debt            
Total Cash2,1452,2982,4832,0792,2062,3312,2362,3852,3471,9871,9822,022
Total Debt1,4101,4171,4471,4431,4441,4541,4521,4901,3611,3691,2241,223
Net Debt / (Cash)-735-881-1,037-635-762-878-783-895-985-618-757-799
Cash Flows Quarterly            
FCF from Operations-151-116-115-120-15033-109-97-134-200-24-18
Cash Flows TTM            
FCF from Operations TTM-502-501-352-346-323-308-541-456-377-27413098
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-27.5%-22.1%-32.7%-16.2%-40.6%-1.9%-43.5%-30.8%-43.3%-60.1%-19.5%-29.6%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-21.8%-23.9%-20.9%-22.4%-26.4%-27.1%-42.1%-40.2%-44.2%-29.6%0.9%-0.7%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Ionis operations788587   
Commercial revenue  342365 
Research and development revenue  468365 
Akcea Therapeutics    489
Elimination of Intercompany Activity    -225
Ionis Core    859
Total7885878107291,123


Net Income by Segment
$ Mil20242023202220212020
Ionis operations-366-270   
Total-366-270   


Price Behavior

IONS Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta0.130.610.450.820.870.73
Up Beta-0.72-0.010.020.820.830.74
Down Beta0.130.150.060.730.750.71
Up Capture31%116%127%105%77%33%
Bmk +ve Days10223571142415
Stock +ve Days12213674130377
Down Capture61%93%-4%77%107%94%
Bmk -ve Days11192754106334
Stock -ve Days9202651118369

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity10,502,338
Short Interest: % Change Since 8152025-2.6%
Average Daily Volume1,766,631
Days-to-Cover Short Interest5.94
Basic Shares Quantity158,735,000
Short % of Basic Shares6.6%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/30/20254.6%3.8%3.1%
4/30/20253.0%6.9%12.2%
2/19/20252.8%-0.2%2.9%
11/6/2024-1.5%-3.2%-2.4%
8/1/20243.8%-5.4%0.9%
5/7/2024-3.2%-8.2%-5.7%
2/21/20241.0%6.9%-1.8%
11/2/2023-3.4%4.0%14.1%
...
SUMMARY STATS   
# Positive121211
# Negative121213
Median Positive2.6%3.5%7.6%
Median Negative-2.6%-3.0%-7.1%
Max Positive5.6%6.9%20.9%
Max Negative-5.0%-12.6%-22.8%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025730202510-Q 6/30/2025
3312025430202510-Q 3/31/2025
12312024219202510-K 12/31/2024
93020241106202410-Q 9/30/2024
6302024801202410-Q 6/30/2024
3312024507202410-Q 3/31/2024
12312023221202410-K 12/31/2023
93020231102202310-Q 9/30/2023
6302023809202310-Q 6/30/2023
3312023503202310-Q 3/31/2023
12312022222202310-K 12/31/2022
93020221109202210-Q 9/30/2022
6302022809202210-Q 6/30/2022
3312022504202210-Q 3/31/2022
12312021225202210-K 12/31/2021
93020211103202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Diaz Allene M. 8262025Sell42.531,42760,687781,151Form
1PARSHALL B LYNNE 8082025Sell41.874,600192,5953,631,841Form
2Geary Richard SEVP, Chief Development Officer8052025Sell42.8610,000428,5933,835,564Form
3Schneider EugeneEVP, Chf Clinical Develop Ofcr8052025Sell42.809,549408,7012,204,520Form
4Monia Brett PChief Executive Officer7142025Sell41.741,16048,4167,505,345Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.